Urocortin 2 in patients with hypertension treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers.

• DOI: 10.26402/jpp.2019.2.15
• Publication Date: 2019-04-01
• Authors: Jolanta Walczewska; Olga Siga; A. Dzieza-Grudnik; Jarosław Królczyk; Barbara Wizner; Paweł Wołkow; A. Borys; Maria Kołton‐Wróż; Barbara Gryglewska; Tomasz Grodzicki
• Keywords: Urocortin

Urocortin 2 (Ucn2) - corticotropin-releasing hormone receptor signalling has favourable effects in the cardiovascular system, including vasodilation, lowering of blood pressure and systemic peripheral resistance, increase cardiac output contractility, as well cardioprotection against ischemia-reperfusion injury. Vasodilation seem to be very interesting important effects, but their mechanism interaction with antihypertensive drugs have not been evaluated. The aim present study was assess relationship between Ucn2 concentration therapy patients primary hypertension. We examined a group 65 hypertension receiving at least 3 drugs. In all them plasma level Ucn2, anthropometric measurements, biochemical tests, ambulatory monitoring (ABPM), echocardiography were performed. There no differences related beta-blockers, calcium channel blockers or diuretics, we observed that treated angiotensin converting enzyme inhibitors (ACEI) (n = 52) serum levels significantly higher than angiotensin-receptor (ARBs) 13) (10.93 versus 5.56 ng/mL; P < 0.05). Moreover, did observe any terms on ABPM, left ventricular mass index, presence diabetes. addition, small subgroup alpha-blockers also found lower coexisting systolic night, ventricle index (LVMI) more frequent occurrences diabetes compared non-alpha-blockers. Our findings suggest hypotensive action renin-angiotensin-aldosterone system blockade may urocortin system. an element mosaic pressure-lowering factors for essential